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Abstract: Human milk oligosaccharides (HMOs) are a major component of human milk, and play an
important role in protecting the infant from infections. Preterm infants are particularly vulnerable,
but have improved outcomes if fed with human milk. This study aimed to determine if the HMO
composition of preterm milk differed from that of term milk at equivalent stage of lactation and
equivalent postmenstrual age. In all, 22 HMOs were analyzed in 500 samples of milk from 25 mothers
breastfeeding very preterm infants (< 32 weeks of gestational age, < 1500 g of birthweight) and 28
mothers breastfeeding term infants. The concentrations of most HMOs were comparable at equivalent
postpartum age. However, HMOs containing α-1,2-linked fucose were reduced in concentration
in preterm milk during the first month of lactation. The concentrations of a number of sialylated
oligosaccharides were also different in preterm milk, in particular 3′-sialyllactose concentrations were
elevated. At equivalent postmenstrual age, the concentrations of a number of HMOs were significantly
different in preterm compared to term milk. The largest differences manifest around 40 weeks of
postmenstrual age, when the milk of term infants contains the highest concentrations of HMOs. The
observed differences warrant further investigation in view of their potential clinical impact.
Keywords: 2′-fucosyllactose (2′FL); 3′-sialyllactose (3′SL); disialyllacto-N-tetraose (DSLNT); human
milk oligosaccharides (HMO); milk group; secretor; Lewis; lactation; preterm
1. Introduction
Human milk is the optimal source of nutrition for infants, and it is widely recommended that
infants are exclusively or predominantly breastfed for the first 6 months of life [1,2]. In preterm neonates,
human milk feeding is known to have several important specific protective actions and it is strongly
encouraged too [1,3,4]. Preterm infants consuming human milk have notably improved immunity [5],
are less likely to develop necrotizing enterocolitis (NEC) [6], have improved neurodevelopmental
outcomes [1,7] and a better long term health outcome [8,9].
However, as nutritional needs of preterm infants are higher compared to those of term infants,
human milk composition may not match the nutritional needs of very preterm infants (< 32 weeks of
gestational age, < 1500g of birthweight) during the first weeks of life. In this context, human milk
fortification in energy, proteins and minerals is commonly recommended in routine nutritional neonatal
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care of very preterm infants [4]. To optimize current practices, additional knowledge on human milk
composition and opportunities in nutrient supplementation remain to be further explored.
While the composition of preterm milk has been investigated [10], and it is reported to be slightly
different from that of term milk [11,12], there are relatively few studies focusing on the human milk
oligosaccharide (HMO) composition of preterm milk.
HMOs are the 4th most abundant component of human milk after water, lipids and lactose, and may
be present at concentrations up to 25 g/L in colostrum and between 10 to 15 g/L in mature milk [13–15].
This family of over 160 compounds [16] is postulated to play an important role in protecting infants
from infection, by acting as decoy receptors or through modulation of the gut microbiota. They may
also modulate the immune system through direct interactions [17–20]. Furthermore, HMOs may act as
a dietary source of sialic acid [21,22], potentially important for learning and memory [23,24]. Recent
evidence from animal studies suggests non-sialylated HMOs may also be important for learning and
memory [25]. Today, randomized placebo controlled trials with HMO supplementation are scarce and
only done with individual HMOs. Trials that have been carried out indicate that 2′FL is associated
with infant immunity [26] and 2′FL together with lacto-N-neotetraose (LNnT) relate to protection from
illnesses of the lower respiratory tract and a reduction in antibiotic use [27].
Of specific relevance to preterm infants, HMOs have been linked to the prevention of gut
dysfunction [28] and development of NEC [28,29]. Disialyllacto-N-tetraose (DSLNT) and 2′FL have
been shown to protect against the development of NEC in rat models [30,31]. It was also observed that
DSLNT was present in lower concentrations in the milk fed to preterm infants who developed NEC
compared to those who did not [32], leading to the proposal that DSLNT could be used as a marker to
predict the likelihood of an infant developing NEC [32].
HMOs are built from lactose, the lactose can be elongated with residues of galactose and
N-acetylglucosamine to produce at least 13 different core oligosaccharides [16,33,34]. The core
oligosaccharides can be further decorated with sialic acid residues by the action of sialylltransferases,
and fucose residues by the action of fucosyltransferases. Due to genetic polymorphisms, two
fucosyltransferases, fucosyltransferase-2 (FUT2) and fucosyltransferase-3 (FUT3) are not active in
100% of the population. Fucosyltransferase-2 (FUT2) is responsible for the attachment of fucose
to core oligosaccharides through an α-1,2-linkage creating HMOs such as 2′-fucosyllactose (2′FL)
or lacto-N-fucopentaose-I (LNFP-I). When FUT2 is inactive such HMOs are absent from the milk.
Fucosyltransferase-3 (FUT3), attaches fucose to the core oligosaccharides through an α-1,4 linkage
creating oligosaccharides such as LNFP-II, and along with other fucosyltransferases HMOs containing
α-1,3 linkages. When FUT3 is inactive HMOs containing α-1,4 linkages are absent from the milk. This
results in there being four major milk groups with differing HMO compositions depending on the
activities of the FUT2 and FUT3 enzymes:
• Milk group 1, in which both enzymes are active
• Milk group 2, in which FUT3 is active but FUT2 is not
• Milk group 3, in which FUT2 is active but FUT3 is not
• Milk group 4, in which both enzymes are inactive.
In general, milk group 1 seems to be the most common milk group, and milk group 4 is
rare [35], however the distribution of milk groups in different populations varies depending on genetic
background [36]. Based on the HMO composition of different milk samples, there is also evidence that
further subgroups may exist [37,38].
There have been a few previous investigations looking at the HMO composition of preterm
milk [17,32,36,39–43], in most cases it is reported that the HMO composition of preterm milk is
comparable to that of term milk. However, Coppa [39] reported that preterm milk contained a higher
total HMO concentration compared to term milk and De Leoz [36] reported that some HMO features
were more variable in preterm milk than in term milk. Kunz [43] pointed out that the Lewis and secretor
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status should be taken in to account when making studies on HMOs, since these are important factors
determining the HMO composition, but milk group has been considered in only a few studies [40–42].
Here we report the composition and trajectories of several different HMOs analyzed in milk
collected from mothers of preterm infants and term infants. The HMO composition was compared at
equivalent stage of lactation (i.e., equivalent infant postnatal age) and at equivalent postmenstrual
age (i.e., equivalent infant developmental stage). In addition the milk group for each donor could be
identified from the HMO composition of the milk, thus comparisons could be performed on samples
with matched milk groups.
2. Materials and Methods
2.1. Trial Design
This research is part of a prospective cohort study to compare the nutritional composition of
human milk from mothers giving birth at term or preterm. The detailed study design has already been
published [44].
The study was conducted at the Neonatal Intensive Care Unit (NICU) and at the maternity ward
of the University Hospital in Lausanne (CHUV), Switzerland, between October 2013 and July 2014.
In this cohort, human milk was longitudinally collected from mothers of preterm infants (gestational
age 28 0/7 weeks to 32 6/7 weeks) and mothers of term infants (gestational age 37 0/7 weeks to 41 6/7
weeks). A dedicated research nurse, qualified as a lactation consultant, followed and supported the
subjects during the study period. Neonatal demographic and delivery data were collected from the
medical charts upon enrollment.
2.2. Milk Collection & Storage
Preterm human milk samples were collected once per week at 7 ± 1 day intervals during the first 8
weeks after delivery. An additional 4 samples were collected until 16 weeks after delivery with sample
collection at 14 ± 1 day intervals. Term human milk samples were collected once per week at 7 ± 1
day intervals during the first 8 weeks after delivery (Figure 1). With such a sampling design, it was
possible to compare preterm milk with term milk at the same stage of lactation (in Figure 1 the preterm
sample at wk1 with the term sample at wk1, etc) or at the equivalent postmenstrual age of the infant
(in Figure 1 samples at 42, 44 and 46 weeks would be compared ie. preterm wk12 with term wk2,
preterm wk14 with term wk4, etc.)
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Figure 1. Example of milk sampling scheme from term and preterm mothers delivering at 
postmenstrual weeks 40 and 30 respectively. Reprinted from Garcia-Rodenas, et al. Clinical Nutrition, 
2018 [44] with kind permission from Elsevier. 
Samples were collected at the first milk expression in the morning between 06:00 and 12:00 using 
an electric, double breast pump (Symphony®, Medela, 6340 Baar Switzerland). Full milk expression 
from a single breast was collected, homogenized, and a 10 mL sample was taken for analysis (except 
for the first 2 visits, when the volume of sample for analysis was 1-3 mL). Milk for analysis was 
transferred to a 15 mL polypropylene tube and stored at -18°C for up to 1 week until hospital transfer 
and then at -80°C. Samples were thawed once, homogenized, and split in to 15 different aliquots for 
Figure 1. Example of milk sampling scheme from term and preterm mothers delivering at postmenstrual
weeks 40 and 30 respectively. Reprinted from Garcia-Rodenas, et al. Clinical Nutrition, 2018 [44] with
kind permission from Elsevier.
Samples were collected at the first milk expression in the morning between 06:00 and 12:00 using
an electric, double breast pump (Symphony®, Medela, 6340 Baar Switzerland). Full milk expression
from a single breast was collected, homogenized, and a 10 mL sample was taken for analysis (except for
the first 2 visits, when the volume of sample for analysis was 1–3 mL). Milk for analysis was transferred
to a 15 mL polypropylene tube and stored at −18 ◦C for up to 1 week until hospital transfer and then at
−80 ◦C. Samples were thawed once, homogenized, and split in to 15 different aliquots for different
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analyses. Those aliquots were then stored at −80 ◦C until analysis or shipment. Aliquots for HMO
analysis were shipped to Neotron S.p.A, Modena, Italy on dry ice.
2.3. Ethical & Legal Considerations
The study was conducted according to the guidelines in the Declaration of Helsinki. The study
was approved by the local ethics committee (Commission cantonale d’éthique de la recherche sur
l’être humain du Canton de Vaud, Switzerland; Protocol 69/13, clinical study 11.39.NRC). Written
informed consent was obtained from all subjects participating in the study. The study was registered
on ClinicalTrials.gov with the identifier NCT02052245.
2.4. Analytical Method
HMOs were analyzed by liquid chromatography with fluorescence detection after labelling
with 2-aminobenzamide using the protocol described by Austin & Benet [45]. Ten HMOs were
quantified against genuine standards with known purity; 2′-fucosyllactose (2′FL), 3-fucosyllactose
(3FL), A-tetrasaccharide (A-Tetra), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 3′-sialyllactose
(3′SL), 6′-sialyllactose (6′SL), Lacto-N-fucopentaose-I (LNFP-I), LNFP-V and Lacto-N-neofucopentaose
(LNnFP). All other HMOs were quantified against maltotriose with known purity, assuming equimolar
response factors (graphical representations of the HMOs studied can be found in supplementary Figure
S1). A pooled human milk sample (Lee Biosolutions, St Louis, USA) was analyzed with every batch of
analysis and at least every 25 injections as a quality control (QC) sample to ensure the method was
performing consistently between analytical batches.
2.5. Assignment to FUT2 and FUT3-Dependant Milk Group
The milk samples were assigned to one of 4 milk groups depending on the levels of 2′FL (a
marker for FUT2 activity) and LNFP-II (a marker for FUT3 activity) in the sample at visit 2 (2 weeks
postpartum). Samples in milk group 1 have high levels (> 25 mg/L) of 2′FL and (>35 mg/L) LNFP-II,
samples in milk group 2 have high levels (> 35 mg/L) of LNFP-II and low levels (< 25 mg/L) of 2′FL,
samples in milk group 3 have high levels (> 25 mg/L) of 2′FL and low levels (< 35mg/L) of LNFP-II,
samples in milk group 4 have low levels (< 25mg/L) of 2′FL and (< 35 mg/L) LNFP-II.
2.6. Data Analysis
All statistical analyses were done with the statistical software R 3.2.3. Prior to statistical analysis
all results below the method limit of quantification (LoQ) were set to a value of 0.5 × LoQ. A mixed
linear model was used in comparing the two groups (preterm and term) in which the group, infant age
(postpartum or postmenstrual) and mode of delivery were considered as fixed effects. The “within
subject” variability is taken into account by declaring the subjects as random effects. The main point of
comparison is preterm vs term infants. An adjustment for mode of delivery was made because it is a
confounding effect with term status given that there are higher proportion of preterm infants delivered
by C-section. A logarithmic transformation was applied to some of the HMO concentrations when
modelling as the distribution was skewed and according to Box-Cox and QQ plots a log-transformation
seemed adequate. Contrast estimates of the model were used to assess significant differences between
preterm and term infants at specified lactation and postmenstrual weeks.
3. Results
3.1. Subject Characteristics
This study included 27 mothers with a total of 33 preterm infants, and 34 mothers with a total
of 34 term infants. Two of the 27 mothers with preterm infants and six of the 34 mothers with term
infants dropped out of the study before completion. No serious adverse events were reported during
the study. A total of 500 milk samples were collected and analyzed for HMO content; 280 preterm
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samples and 220 term samples. The study flow chart and detailed demographic and anthropometric
data have already been reported [44]. In summary, baseline maternal characteristics were not different
between the two groups, and all mothers in both groups were healthy. Delivery by cesarean section
was more common in the preterm group, as were multiple deliveries (twins). Unsurprisingly, term and
preterm infants differed in gestational age, birth weight, height and head circumference. There was no
difference in gender distribution.
3.2. Milk Groups
The milk samples were assigned to one of 4 milk groups. Overall, 75% of samples were assigned
to milk group 1, 19% to milk group 2, 4% to milk group 3 and 2% (1 individual) to milk group 4
(Figure 2). Milk group distribution was similar in the preterm and term populations.
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Figure 2. Distribution of milk groups in the different populations: All = all participants, P = participants
with preterm infants, T = participants with term infants, G1 = milk group 1, G2 = milk group 2,
G3 = milk group 3, G4 = milk group 4.
3.3. Changes in Concentration uring Lactation
For both term and preterm ilk, the concentration of many of the HMOs decreased at later stages
of lactation (Figure 3, and Supplementary Table S1), of those LNT, DSLNT, LNDFH-I, MFLNH-III and
DFL a reached their maximum concentration after the first week postpartum (i.e., at weeks 2 or 3
postpartum). The only HMO to increase in concentration at later stages of lactation was 3FL.
3.4. HMO Concentration in Term versus Preterm Milk at Equivalent Postpartum Age (Lactation Stages)
Considering all samples, when the children were the same age postpartum, the c ncentration
of each HMO in the mother’s milk was generally comparable between term and preterm groups
(Figure 3 and Supplementary Table S1). The main exceptions to this were 3′SL, LSTb and DSLNT all of
which were at significantly higher concentrations in the preterm milk at postpartum weeks 2 to 8. The
concentrations of LSTc (at weeks 1 to 4) and 6′SL (at weeks 2 to 4) were higher in term milk during the
first month, but were not significantly different at later time points.
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Figure 3. Mean concentration of each HMO at each visit for term (grey) and preterm (white) infants,
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Comparing term and preterm milk at the same age postpartum, but restricting the comparison
to milks within the same milk group the picture changes slightly (Figure 4, Figure 5, Supplementary
Figure S2, and Supplementary Table S2). Within samples from milk group 1, LNFP-I concentrations are
significantly higher in term milk at weeks 1-4, 2′FL concentrations are significantly higher in term milk
samples at weeks 1-3 and DFLNHa concentrations are significantly higher in term milk samples at
weeks 3-4 (Figure 4). These three HMO do not occur in group 2 or group 4 milks. The concentration of
3′SL remains significantly higher in group 1 preterm milk at weeks 2-8, but for DSLNT the difference
between term and preterm milk is only significant at weeks 5 and 8 and for LSTb only at weeks 5, 6 and
8 (Figure 5). For 6′SL, the differences observed between term and preterm is lost when considering only
group 1 milk and for LSTc the difference between term and preterm group 1 milk is only significant
at weeks 2 to 3 (Figure 5). For the group 2 milks (Supplementary Figure S2) there are only 5 subjects
in the term and 5 subjects in the preterm group so statistical significance was not tested at each visit.
However from Figure 5 it can be seen that LNFP-V, 3′SL, 6′SL and DSLNT concentrations appear
numerically much higher in preterm group 2 milk than term group 2 milk, while 6′SL and LSTc, appear
numerically higher in term group 2 milk, especially in the first month. For group 3 milk there was only
1 subject in the term group and 1 subject in the preterm group so a comparison was not made, and for
group 4 milk we had only one subject in the whole study.
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3.5. HMO Concentration in Term versus Preterm Milk at Equivalent Postmenstrual Age
(Developmental Status)
When the milks are compared at infants’ equivalent postmenstrual age (Figure 6 and
Supplementary Table S3), the concentrations of several HMOs (2′FL, 3′GL, 3′SL, 3FL, 6′GL, 6′SL,
DFLNHa, DSLNT, LNFP-I, LNnDFH, LNnT, LNT, LSTc, MFLNH-III) are different at 2 or more visits
in the preterm milk compared to term milk. The differences tend to manifest at weeks 38-41 where
the concentration of several HMOs in term milk are at their maximum, and the concentration of
3FL is at the minimum. Thus, at equivalent developmental status, preterm infants consume higher
concentrations of 3FL in their milk than term infants. However the preterm infants consume lower
concentrations of most other HMOs. Making the same exercise only on milk group 1 samples (Figure 7
and Supplementary Table S4) doesn’t change this a lot although the magnitude and the duration of
some differences (especially for 2′FL and LNFP-I) does change. Similar plots for milk group 2 are
reported in Supplementary Figure S3, but no statistical analyses have been performed due to the low
number of subjects.
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4. Discussion
In this study we have compared the content of 22 HMOs of 500 breast milk samples from mothers
of preterm infants and term infants over time. The comparison has been performed both by equivalent
stage of lactation (postpartum age) or equivalent postmenstrual age (developmental stage).
4.1. HMO in Term vs Preterm Milk at Equivalent Postpartum Age (Lactation Stages)
The HMO concentrations and trajectories over lactation were generally comparable in the milk of
mothers giving birth preterm and term, but several important differences were observed, in particular
for the sialylated oligosaccharides. This contrasts some of the previous studies [40,43,46] in which
no significant differences were observed in HMO concentrations between term and preterm milk.
Coppa et al. [39] reported that the sum of the measured HMOs in preterm milk was significantly higher
than that of term milk at day 4 postpartum, but not at days 10 or 30 postpartum. Gabrielli et al. [41]
also reported that concentrations of HMOs were higher in preterm milk, but did not go in to details.
In this study, we observed the HMOs carrying sialic acid residues, 3′SL, LSTb and DSLNT, were
present at significantly higher concentrations in preterm milk between weeks 2-8, while 6′SL (at
weeks 2-4) and LSTc (at weeks 1-4) were higher in term milk. Wang et al. [47] reported that the total
sialic acid content of preterm milk was significantly higher than that of term milk up to 45 days
postpartum, but not beyond 92 days postpartum. In this study we did not collect milk from term
infants beyond 56 days postpartum. Although our data appear to be in line with the observations of
Wang et al. [47], they contradict the data of Kunz et al. [43] and Spevacek et al. [46] who did not report
differences in concentrations of sialylated HMO between term and preterm milk. Variability in HMO
concentration between individuals is high, and both of these studies were slightly smaller than ours,
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which is itself rather small. As pointed out by Kunz et al. [43] it is difficult to compare quantitative
HMO results between studies, due to the lack of standardized methods of analysis, milk collection
timing and milk collection methodology. Further, although some studies have considered the impact
of milk group and stage of lactation on HMO concentrations, they have not matched both stage of
lactation and milk group prior to comparing term vs preterm milk, which could mask (or enhance) any
compositional differences.Nutrients 2019, 11, 1282 9 of 17 
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As to why we observed higher concentrations of several sialylated HMOs in preterm milk
and lower concentrations of other sialylated HMOs, we can only speculate. From a structural
viewpoint, 6′SL and LSTc, both at higher concentrations in term milk, both contain the structural m tif
α-Neu5Ac(2→6)β-D-Gal- which is absent fr m 3′SL, LSTb and DSLNT. 3′SL, LSTb and DSLNT all
contain the structural motifsα-Neu5Ac(2→6)β-D-GlcNAc- and/orα-Neu5Ac(2→3)β-D-Gal-. Therefore
we may envisage that the sialyltransferase responsible for attaching sialic acid to galactose through an
α-1,6-linkage has reduced activity after preterm delivery while those responsible for attaching sialic
acid through an α-1,3 linkage to galactose or an α-1,6-linkage to N-acetylglucosamine have increased
activity. During the final trimester of gestation, the ganglioside density of the cerebral cortex increases
significantly [48], and sialic acids are an i portant component of the gangliosides. One may also
postulate that at this stage of gestation the mother has an increased production of sialic acid to help
with the baby’s brain development. If the baby is born prematurely, and lactation begins early, the
upregulation of the system to produce sialic acids ay result in an increased production of sialylated
HMOs. Dietary sources of sialic acid have been demonstrated to be processed by the body and the
sialic acids incorporated in to glycoproteins [49]. Data from Wang et al. [24] have also demonstrated
that supplementing pigs’ diets with a dietary source of sialic acid improves learning and memory.
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The higher concentration of sialylated HMOs in preterm milk may be a factor that contributes to the
important benefits experienced by preterm infants consuming their own mothers’ milk.
DSLNT has been observed to protect neonatal rats from development of NEC [30]. An observational
study in preterm human infants also observed that infants receiving milk with higher levels of DSLNT
were less likely to develop NEC [32] leading to the proposition that DSLNT concentrations could be
used as a possible marker for risk of developing NEC. This work demonstrates that the mothers own
milk of preterm infants is probably a good source of DSLNT. Our data also suggest children receiving
group 2 milk may receive higher concentrations of DSLNT than those receiving group 1 milk, but a
larger study would be needed to test if the difference is significant, and to determine if infants receiving
group 2 milk may be better protected from NEC.
4.2. HMO at Equivalent Postmenstrual Age (Developmental Status)
As shown above, when comparisons were made at equivalent postpartum age, there were few
differences in concentrations of most HMOs between term milk and preterm milk and the trajectories
of concentration during lactation were comparable. This can indicate that birth sets off a program
that defines the HMO trajectory with most HMOs showing a decrease in concentration with stage of
lactation with the exception of 3FL, which increases.
Since the HMO concentration varies with stage of lactation, when the milk is compared at infants’
equivalent postmenstrual age, the concentrations of most of the HMOs in preterm milk are lower than
in the term milk, with the exception of 3FL (since it increases during lactation) and 3′SL (since it is
generally in higher concentrations in preterm milk). The largest differences manifest around 40 weeks
of postmenstrual age, which is when the milk for term infants contains the highest concentrations of
HMOs. Interestingly, as the postmenstrual age increases, the differences reduce, and for some HMOs
the concentrations are equivalent by 44-46 weeks postmenstrual age, while for some others a significant
difference was maintained for the duration of the study. The biological relevance of these differences is
unclear, and would be worthy of future investigation. Making the hypothesis that infants need to be
exposed to a certain amount of HMOs at specific stages of their development, we can presume that
preterm infants may be losing out by being exposed to lower amounts of HMOs than term infants as
similar stages of development. In such a case supplementing preterm milk with HMOs is likely to be
beneficial. Alternatively, perhaps the HMOs help the infant adjust to life outside the womb, and the
concentrations in the mothers’ milk are appropriate. However a very preterm infant may not receive
full enteral feeding until several days or even weeks after delivery, meaning that the actual amount of
HMOs they receive will be below what they would be receiving if they could be immediately fully
breast fed. In such cases HMO supplementation may also be beneficial. Clinical evidence shows that
premature infants greatly benefit from being fed own mother’s milk [3,50], or, alternatively, being fed
donor human milk [50]. For very preterm infants the milk needs to be fortified with energy, proteins
and minerals [3]. Now that HMOs start to be commercially available, HMO fortification is also possible,
but further work is needed to confirm the potential benefits and the appropriate timing and dosages
for intervention.
4.3. Impact of Milk Group
In general, when comparing HMO compositions, it is important to consider the milk group. In
this study the distribution of milk groups is comparable between mothers giving birth term or preterm,
with the majority of mothers producing group 1 milk (milk containing oligosaccharides indicating
both FUT2 and FUT3 were active). Milk group 2 was next most common with 5 mothers in each group.
The equal distributions suggest that there is no link between the genetic factors controlling the milk
groups, and the likelihood of giving birth prematurely, although this study is too small to properly
address this question.
In this study, when combining data from all milk groups at the same postpartum stages it appears
that there was relatively little difference in the concentrations of the neutral HMOs between term or
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preterm milk, similar to what has been observed previously [40,43,46]. However when only the group
1 milks were compared, three neutral HMOs, 2′FL, LNFP-I, and DFLNHa, were at significantly lower
concentrations in preterm milk during the first month of lactation. 2′FL was 700-800 mg/L (20–27%)
lower, LNFP-I was 420–590 mg/L (27–32%) lower and DFLNHa was 60-70 mg/L (26–30%) lower. These
differences were hidden by the increased variability introduced by the inclusion of the data from
the other milk groups, especially milk group 2 with inactive FUT2. All of these structures contain
α-1,2-linked fucose residues and are present in significant concentrations only in milk of groups 1 and
3. The observation that these structures are at lower concentrations in group 1 preterm milk implies
that the fucosyltransferase-2 enzyme (FUT2) is not fully active during the first month of lactation when
an infant is born very preterm as suggested previously [36]. Higher levels of fucosylation have been
shown to increase protection against infection [18] but the clinical relevance of the magnitude of the
differences remains to be assessed.
Interestingly in group 1 milk, 3′SL is the only sialylated HMO that remains higher in preterm
milk across weeks 2-8 (as observed when studying all milk groups together). The differences in
concentrations of LSTb and DSLNT between term and preterm milks are largely lost, the differences
being significant only at 2 or 3 non-consecutive time points. Likewise for 6′SL and LSTc, which
were observed as being significantly higher in term milk when all milk groups were combined, the
significance is largely lost when considering only milk group 1 data. Most of the differences in
concentrations of sialylated structures appears to be driven by their concentrations in the group 2 milks
(Figure 5). The reasons for this are not clear, but one may postulate that FUT2 outcompetes the other
enzymes for access to the core structures, and so when FUT2 is active (even if slightly less active than
normal for preterm milks), the difference in activity of the sialyltransferases is masked. However,
when FUT2 is not active, the difference in sialyltransferase activities becomes more apparent.
Looking at differences in HMO concentrations at equivalent postmenstrual age, and considering
only milk group 1 (Figure 7), does not much change the observations made considering all milk
groups (Figure 6) with most of the differences being driven by the stage of lactation. However, it does
emphasize the differences in the HMOs containing α-1,2-linked fucose. For example looking at all
milk groups, 2′FL concentrations appear significantly different only between weeks 39-41, but when
considering only milk group 1 then the concentration differences are significant between weeks 39-43
and at week 45. Similar phenomena can be observed for LNFP-I and LNDFH-I. This highlights the
importance of considering milk group when making comparisons between different milk samples.
4.4. Strengths and Limitations of the Study
The main limitations of this study are the limited sample size and the monocentric design of the
study. One may also argue that collecting milk at only one time of the day, the first milk expression in
the morning, may mean the data are not representative of the milk composition during the whole day.
Conversely one may see this as a strength of the study, since the main aim was to compare term versus
preterm milk and sampling at different times of the day could have introduced additional variation not
specifically related to the comparison of term versus preterm milk. Certainly a strength of the study
was the very tight collection windows at each stage of lactation, each window being only ±1 day. It is
well established that the HMO concentration changes at different stages of lactation [51–56], especially
during the first few months of lactation. Keeping the milk collection window tight reduces variability
due to differences in sampling day. The study protocol places quite a burden on the mothers who need
to collect the full milk expression from a single breast at every sampling point. Despite this, we had
very few drop outs from the study, the support provided to the mothers by the lactation nurse was
surely a key factor in the successful retention of the volunteers. Importantly, the analytical method used
for determination of the HMOs has been extensively validated [45]. To ensure the method performance
was maintained day to day, a reference sample of pooled human milk was analysed with every batch
of analyses, and at least every 25 samples. Such rigor assured that the variability introduced by the
analytical method was also kept to a minimum. Milk group assignments have been done based on
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the concentrations of 2′FL and LNFP-II in the milk. Appropriate cut-off concentrations for making
milk group assignments have not yet been established, so we have based our cut-offs based on the
performance of the analytical method. Unfortunately, due to the small sample size, it was not possible
to make statistical comparisons between term and preterm milk of milk groups 2,3 or 4. In this study
we have only determined the concentrations of 22 out of over 160 HMOs. Although those 22 include
the most abundant HMOs, concentrations of a large number of HMOs and how they are impacted by
preterm birth remains unknown.
5. Conclusions
The HMO composition and concentration trajectory of term and preterm milk are largely
comparable at equivalent infant postpartum age, suggesting that birth triggers a program that defines
the HMO trajectory during lactation. Consequently, significant differences exist between preterm
and term infants milk when comparing HMO concentrations at equivalent postmenstrual ages.
Nevertheless some differences were observed when the comparison was made at the same postpartum
age, in particular for the sialylated oligosaccharides and oligosaccharides containing α-1,2-linked
fucose. The data suggest that when an infant is born preterm, FUT2 is not fully active during the first
month of lactation, leading to reduced concentrations of HMOs such as 2′FL and LNFP-I. In addition
the expression of enzymes responsible for sialyllation of HMOs is also perturbed leading to differences
in concentrations of the sialylated HMOs. Interestingly, these observations are not fully consistent with
previous studies in preterm infants. This study was small, thus the observations need corroboration in
larger cohorts. The possible physiological significance of the observations remain to be determined.
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